TLR4 and breast carcinoma: Importantly, this synergistic effect is particularly pronounced in TLR4-positive MDA-MB-231 breast cancer cells, while the effect is less evident in HCC1806 cells that lack TLR4, underscoring the critical role of TLR4 in the therapeutic combination of hyperoside and paclitaxel.